IL114343A0 - Use of IGF-I in the prevention of diabetes - Google Patents

Use of IGF-I in the prevention of diabetes

Info

Publication number
IL114343A0
IL114343A0 IL11434395A IL11434395A IL114343A0 IL 114343 A0 IL114343 A0 IL 114343A0 IL 11434395 A IL11434395 A IL 11434395A IL 11434395 A IL11434395 A IL 11434395A IL 114343 A0 IL114343 A0 IL 114343A0
Authority
IL
Israel
Prior art keywords
diabetes
igf
subject
high risk
prevention
Prior art date
Application number
IL11434395A
Other languages
English (en)
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of IL114343A0 publication Critical patent/IL114343A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11434395A 1994-07-04 1995-06-26 Use of IGF-I in the prevention of diabetes IL114343A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9402370A SE9402370D0 (sv) 1994-07-04 1994-07-04 Use of IGF-I

Publications (1)

Publication Number Publication Date
IL114343A0 true IL114343A0 (en) 1995-10-31

Family

ID=20394633

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11434395A IL114343A0 (en) 1994-07-04 1995-06-26 Use of IGF-I in the prevention of diabetes

Country Status (10)

Country Link
US (2) US6342227B1 (xx)
EP (1) EP0759776B1 (xx)
JP (1) JPH10502367A (xx)
AT (1) ATE223729T1 (xx)
AU (1) AU689922B2 (xx)
CA (1) CA2194403A1 (xx)
DE (1) DE69528168T2 (xx)
IL (1) IL114343A0 (xx)
SE (1) SE9402370D0 (xx)
WO (1) WO1996001124A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
EP1165119B1 (en) 1999-04-08 2003-10-08 Genentech, Inc. Composition based on oppositely-charged polypeptides
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
ATE439378T1 (de) 2001-02-09 2009-08-15 Genentech Inc Verfahren zur identifizierung von indirekten igf- 1-agonisten
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2011004051A1 (es) 2009-07-10 2011-01-13 Universidad Autónoma De Barcelona Composiciones de terapia génica para prevenir y/o tratar enfermedades autoinmunes
US10799564B1 (en) * 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486216T2 (de) 1983-04-25 1994-02-17 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.
US4963665A (en) 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1

Also Published As

Publication number Publication date
WO1996001124A1 (en) 1996-01-18
DE69528168D1 (de) 2002-10-17
AU689922B2 (en) 1998-04-09
EP0759776B1 (en) 2002-09-11
JPH10502367A (ja) 1998-03-03
CA2194403A1 (en) 1996-01-18
AU2940795A (en) 1996-01-25
SE9402370D0 (sv) 1994-07-04
ATE223729T1 (de) 2002-09-15
US20020132772A1 (en) 2002-09-19
EP0759776A1 (en) 1997-03-05
US6342227B1 (en) 2002-01-29
DE69528168T2 (de) 2003-01-09

Similar Documents

Publication Publication Date Title
ES2001996A6 (es) Procedimiento para preparar composiciones farmaceuticas contra enfermedades cronicas de trasplante frente a hospedante y contra enfermedades de autoinmunidad.
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
AU7320387A (en) Prevention of outgassing in polyvinylsiloxane elastomers by the use of finely divided platinum black
AU4233185A (en) Fastener, particularly suited for orthopedic use
AU2071988A (en) Haloarylnitrile degrading gene, its use, and cells containing the gene
ES8606289A1 (es) Un procedimiento para la preparacion de piridazinaminas.
IL114343A0 (en) Use of IGF-I in the prevention of diabetes
AU5243486A (en) Injector with dosage mechanism
AU1870088A (en) Expression of the protase inhibitor human alpha-1-antitrypsin yeast cells using glycolytic promoters
GB9806632D0 (en) Peptide factor
Dolgopolsky The Indo-European homeland and lexical contacts of Proto-Indo-European with other languages
DE3170587D1 (en) The use of peptides as medicaments and certain novel peptides
AU8727382A (en) Medical liquid squeeze-bottle with non-return valve
AU576998B2 (en) Battery saver
AU8759682A (en) Human insulin and human proinsulin formulations
AU551879B2 (en) Human proinsulin and human c-peptide
AU574978B2 (en) Method for treatment of antidiuresis employing serine derivatives
USD287881S (en) Incontinence pad
AU571073B2 (en) Pharmaceutical composition of 9a, 11b-dichcoro-16a-methl-21-oxycarbonyl dicyclohexycmethycoxy pregna-1,4-diene-3,20-dione
AU551734B2 (en) Human proinsulin and human c-peptide and human insulin formulations
TW269074B (en) Circuit which includes cells with high fanout requirements which has a reduced RC delay
ATE36333T1 (de) Hydantoin enthaltende therapeutische mittel.
RO92445B1 (ro) Unguent medicamentos cu actiune antiinflamatoare, cicatrizanta si epitelizanta
Storm The contact hypothesis and factors affecting the integration of women in the Canadian military.
New Evaluation of Nursing Services in 1970's and Issues of Nursing in 1980's-Public Health Nursing Association